About Optimer Pharmaceuticals (NASDAQ:OPTR)
Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on developing and commercializing hospital specialty products. The Company's development is focused on products that treat gastrointestinal infections and related diseases. Its two products OPT-822/821 and CEM-101 (OP-1068) are in clinical development. Optimer's products include Fidaxomicin and Solithromycin under anti-infectives, and OPT-822/821 under other therapeutic areas. In January 2011, its majority owned subsidiary, Optimer Biotechnology, Inc. (OBI) conducted a Phase 2/3 clinical, trial to evaluate OPT-822/821for the treatment of metastatic breast cancer. On May 27, 2011, the United States Food and Drug Administration (FDA) approved DIFICID(fidaxomicin) tablets, its antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). In October 2013, Cubist Pharmaceuticals, Inc announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
Optimer Pharmaceuticals (NASDAQ:OPTR) Frequently Asked Questions
What is Optimer Pharmaceuticals' stock symbol?
Optimer Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPTR."
Who are some of Optimer Pharmaceuticals' key competitors?
Some companies that are related to Optimer Pharmaceuticals include Apple (AAPL), Alphabet (GOOGL), Alphabet (GOOG), Amazon.com (AMZN), Microsoft (MSFT), Facebook (FB), Intel (INTC), Cisco Systems (CSCO), Comcast (CMCSA), PepsiCo (PEP), Netflix (NFLX), Nvidia (NVDA), Amgen (AMGN), Adobe Systems (ADBE), Booking (BKNG), Texas Instruments (TXN), Broadcom (AVGO) and Gilead Sciences (GILD).
Has Optimer Pharmaceuticals been receiving favorable news coverage?
News coverage about OPTR stock has trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Optimer Pharmaceuticals earned a news impact score of 0.14 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 47.59 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Optimer Pharmaceuticals?
Shares of OPTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Optimer Pharmaceuticals?
Optimer Pharmaceuticals' mailing address is 101 Hudson St Ste 3501, JERSEY CITY, NJ 07302-3915, United States. The biopharmaceutical company can be reached via phone at +1-201-3338819.
MarketBeat Community Rating for Optimer Pharmaceuticals (OPTR)MarketBeat's community ratings are surveys of what our community members think about Optimer Pharmaceuticals and other stocks. Vote "Outperform" if you believe OPTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
Optimer Pharmaceuticals (NASDAQ:OPTR) Analyst Ratings History
(Data available from 4/23/2016 forward)
|Date||Brokerage||Action||Rating||Price Target||Impact on Share Price||Details|
Optimer Pharmaceuticals (NASDAQ:OPTR) Earnings History and Estimates Chart
Optimer Pharmaceuticals (NASDAQ OPTR) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/1/2013||Q2 2013||($0.62)||($0.55)||$21.31 million||$20.10 million||View||N/A|
|5/9/2013||Q1 2013||($0.46)||($0.65)||$21.09 million||$19.43 million||View||N/A|
|2/28/2013||Q4 2012||($0.57)||$0.02||$18.05 million||$19.50 million||View||N/A|
|11/1/2012||Q312||($0.63)||($0.56)||$16.03 million||$17.89 million||View||N/A|
Optimer Pharmaceuticals (NASDAQ:OPTR) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Optimer Pharmaceuticals (NASDAQ OPTR) Insider Trading and Institutional Ownership History
Optimer Pharmaceuticals (NASDAQ OPTR) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|4/8/2013||Pedro Lichtinger||CEO||Sell||148,000||$14.69||$2,174,120.00|| |
|11/8/2012||Pedro Lichtinger||CEO||Buy||11,000||$9.08||$99,880.00|| |
Optimer Pharmaceuticals (NASDAQ OPTR) News Headlines
Optimer Pharmaceuticals (NASDAQ:OPTR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Optimer Pharmaceuticals (NASDAQ:OPTR) Income Statement, Balance Sheet and Cash Flow Statement
Optimer Pharmaceuticals (NASDAQ OPTR) Stock Chart for Monday, April, 23, 2018